Instituto Médico de la Fundación Estudios Clínicos - Rosario
El Instituto Médico de la Fundación Estudios Clínicos es una institución dedicada al desarrollo de las ciencias médicas, apoyando toda inquietud científica. Promueve el desarrollo de Estudios Clínicos, entendiéndolo como oportunidad y posibilidad para el desarrollo de medicamentos o procedimientos que permitan el mejoramiento de la calidad de vida de los pacientes.Italia 428, Rosario - Santa Fe
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Onco / Hemato - Investigador PrincipalLaura Pussetto
Oncología - Sub investigadoraLeticia Maria Bruno
Oncología - Sub investigadorJuan Fernando Piana
Psiquiatría - Sub InvestigadoraAzul Milacher
Oncología - Sub investigadoraVirginia Van Kemenade
Oncología - Sub investigadorEsteban Cereigido
Cardiología - Sub investigadora Amaru Lopez
Cardiología - Sub investigadorFederico Ferraro
Psiquiatría - Sub investigadorSebastian Romero
Neumonología / Vacunas - Investigador PrincipalTomas Alvarez
Sub investigadoraDiego Ferreyra
Pediatría - Investigadora PrincipalVeronica Salinas
Neumonología - Sub InvestigadoraBarbara Diaz Salin
Sub investigadoraAngelina Fracaroli
Sub investigadoraFlorencia Corbacho
Pediatría - Investigadora PrincipalMaria Fernanda Maccario
Pediatría - Sub investigadoraEvangelina Montani
Pediatría -Investigador PrincipalRenanta Weimscherman
Endocrinología - Investigador PrincipalMercedes Schiavoni
Dermatología - Investigador PrincipalClara Bernardini
Gastroenterologia - Investigador PrincipalHernan Taquia
Investigador PrincipalMaria Noelia Bersano
Cardiología - Investigador PrincipalEzequiel Vottero
Obesidad - Sub investigadoraJosefina Escudero
Sub investigadoraMaria Sol Dichiara
Onco / Hemato - Investigadora PrincipalGustavo Braidot
Nefrología - Investigador PrincipalJuan Andrés Oddino
Psiquiatría - Investigador PrincipalJavier Travella
Oncología - Investigador PrincipalGabriel Garbaos
Oncología - Investigador PrincipalBetiana Romitelli
Sub investigadoraAna Sol Capelleti
Neumonologia - Investigador PrincipalNadia Brandan
Alergista / Asma - Investigador PrincipalGabriel Gattolin
Open studies
Lung cancer
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer - STAR-121 - Arcus Biosciences, Inc.See more
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC - MB12-C-01-22 - Laboratorio Elea Phoenix S.A.See more
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. - eVOLVE-Lung02 - AstraZenecaSee more
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - INTerpath-002 - Merck Sharp & Dohme LLCSee more
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) - WU-KONG28 - Dizal PharmaceuticalsSee more
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) - MK-1084-004 - Merck Sharp & Dohme LLCSee more
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) - ARTEMIDE-Lung02 - AstraZenecaSee more
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC - ARTEMIDE-Lung03 - AstraZenecaSee more
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) - INTerpath-009 - Merck Sharp & Dohme LLCSee more
Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) - lidERA - Hoffmann-La RocheSee more
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) - CAPItello-292 - AstraZenecaSee more
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer - TROPION-Breast05 - AstraZenecaSee more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) - MK 2870-010 - Merck Sharp & Dohme LLCSee more
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) - DYNASTY-Breast02 - BioNTech SESee more
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) - Merck Sharp & Dohme LLCSee more
Asthma
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) - KALOS - AstraZenecaSee more
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma - FLASH - AstraZenecaSee more
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma - INC 54707-208 - Incyte CorporationSee more
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) - Regeneron PharmaceuticalsSee more
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma - PERFORM - GlaxoSmithKlineSee more
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations - FLAIR - Teva Branded Pharmaceutical Products R&D, Inc.See more
Rare diseases
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease - Moonscape - Genentech, Inc.See more
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity - Oasiz - Horizon Therapeutics Ireland DACSee more
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) - ATHENA-SSc-ILD - Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)See more
Chronic obstructive pulmonary disease
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) - PILLAR - Chiesi Farmaceutici S.p.A.See more
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD - TRITON - Chiesi Farmaceutici S.p.A.See more
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease - THARROS - AstraZenecaSee more
Pulmonary fibrosis
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease - Moonscape - Genentech, Inc.See more
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis - ALOFT-IPF - Bristol-Myers SquibbSee more
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis - ALOFT-PPF - Bristol-Myers SquibbSee more
Cardiovascular disease
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and CompanySee more
Kidney cancer
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma - STELLAR-304 - ExelixisSee more
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). - INTerpath-004 - Merck Sharp & Dohme LLCSee more
Urticaria
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines - Novartis PharmaceuticalsSee more
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria - EMBARQ-CSU1 - Celldex TherapeuticsSee more
Bile Duct Cancer
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer - JZP598-302 - Jazz PharmaceuticalsSee more
Chronic bronchitis
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) - PILLAR - Chiesi Farmaceutici S.p.A.See more
Colorectal cancer
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis - ADorable-1 - Dermira, Inc.See more
Elevated Lipoprotein A
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and CompanySee more
Esophageal cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) - LEAP-014 - Merck Sharp & Dohme Corp.See more
Gastrointestinal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) - REJOICE-GI01 - Merck Sharp & Dohme LLCSee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Interstitial Lung Disease
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) - ATHENA-SSc-ILD - Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)See more
Leukemia
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Lymphoma
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Multiple myeloma
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) - SUCCESSOR-2 - Bristol-Myers SquibbSee more
Nephropathy
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression - IMAGINATION - Hoffmann-La RocheSee more
Non-Hodgkin Lymphoma
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) - waveLINE-010 - Merck Sharp & Dohme LLCSee more
Obesity
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) - ESsCAPE - BiotestSee more
Renal disease
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Schizophrenia
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) - CONNEX-1 CONNEX-2 CONNEX-3 - Boehringer IngelheimSee more
Skin cancer
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007). - V940-007 - Merck Sharp & Dohme LLCSee more
Ulcerative colitis
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) - LUCENT 3 - Eli Lilly and CompanySee more
